Treatment strategies for giant pituitary adenomas in the era of endoscopic transsphenoidal surgery: a multicenter series.

医学 外科 垂体腺瘤 尿崩症 颅咽管瘤 神经外科 垂体瘤 鼻内镜手术 垂体瘤 腺瘤 内窥镜检查 回顾性队列研究
作者
Alexander Micko,Matthew S Agam,Andrew Brunswick,Ben A. Strickland,Martin J. Rutkowski,John D. Carmichael,Mark S. Shiroishi,Gabriel Zada,Engelbert Knosp,Stefan Wolfsberger
出处
期刊:Journal of Neurosurgery [Journal of Neurosurgery Publishing Group]
卷期号:-1: 1-10
标识
DOI:10.3171/2021.1.jns203982
摘要

OBJECTIVE Given the anatomical complexity and frequently invasive growth of giant pituitary adenomas (GPAs), individually tailored approaches are required. The aim of this study was to assess the treatment strategies and outcomes in a large multicenter series of GPAs in the era of endoscopic transsphenoidal surgery (ETS). METHODS This was a retrospective case-control series of 64 patients with GPAs treated at two tertiary care centers by surgeons with experience in ETS. GPAs were defined by a maximum diameter of ≥ 4 cm and a volume of ≥ 10 cm3 on preoperative isovoxel contrast-enhanced MRI. RESULTS The primary operation was ETS in all cases. Overall gross-total resection rates were 64% in round GPAs, 46% in dumbbell-shaped GPAs, and 8% in multilobular GPAs (p < 0.001). Postoperative outcomes were further stratified into two groups based on extent of resection: group A (gross-total resection or partial resection with intracavernous remnant; 21/64, 33%) and group B (partial resection with intracranial remnant; 43/64, 67%). Growth patterns of GPAs were mostly round (11/14, 79%) in group A and multilobular (33/37, 89%) in group B. In group A, no patients required a second operation, and 2/21 (9%) were treated with adjuvant radiosurgery. In group B, early transcranial reoperation was required in 6/43 (14%) cases due to hemorrhagic transformation of remnants. For the remaining group B patients with remnants, 5/43 (12%) underwent transcranial surgery and 12/43 (28%) underwent delayed second ETS. There were no deaths in this series. Severe complications included stroke (6%), meningitis (6%), hydrocephalus requiring shunting (6%), and loss or distinct worsening of vision (3%). At follow-up (mean 3 years, range 0.5-16 years), stable disease was achieved in 91% of cases. CONCLUSIONS ETS as a primary treatment modality to relieve mass effect in GPAs and extent of resection are dependent on GPA morphology. The pattern of residual pituitary adenoma guides further treatment strategies, including early transcranial reoperation, delayed endoscopic transsphenoidal/transcranial reoperation, and adjuvant radiosurgery.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
筱璞羲发布了新的文献求助10
1秒前
Xxxxzzz完成签到,获得积分10
1秒前
2秒前
领导范儿应助缓慢的孤兰采纳,获得10
2秒前
mjj发布了新的文献求助10
3秒前
今我来思发布了新的文献求助10
5秒前
5秒前
6秒前
SciGPT应助韩韩采纳,获得10
6秒前
SciGPT应助xzf1996采纳,获得10
8秒前
生动依凝完成签到,获得积分10
8秒前
刘小文完成签到 ,获得积分10
8秒前
Two完成签到,获得积分10
9秒前
可爱的函函应助今我来思采纳,获得10
9秒前
9秒前
10秒前
10秒前
犹豫晓啸发布了新的文献求助10
10秒前
识字岭的岭应助吕小布12采纳,获得10
10秒前
ding应助MCFCSH采纳,获得10
11秒前
12秒前
李星翰完成签到,获得积分10
14秒前
huiwanfeifei发布了新的文献求助10
14秒前
筱璞羲发布了新的文献求助10
15秒前
17秒前
核桃发布了新的文献求助10
18秒前
uppercrusteve完成签到,获得积分10
19秒前
19秒前
传奇3应助阔达妙柏采纳,获得30
20秒前
20秒前
量子星尘发布了新的文献求助10
21秒前
CHyaa完成签到,获得积分10
21秒前
Serendipity完成签到,获得积分10
21秒前
无花果应助Vme50采纳,获得10
21秒前
科研通AI6.1应助JeremyKarmazin采纳,获得10
23秒前
小马甲应助伶俐的星月采纳,获得10
24秒前
追寻完成签到 ,获得积分10
24秒前
朴二蛋发布了新的文献求助10
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Relation between chemical structure and local anesthetic action: tertiary alkylamine derivatives of diphenylhydantoin 1000
Signals, Systems, and Signal Processing 610
Discrete-Time Signals and Systems 610
Principles of town planning : translating concepts to applications 500
Iron‐Sulfur Clusters: Biogenesis and Biochemistry 400
Healable Polymer Systems: Fundamentals, Synthesis and Applications 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 纳米技术 有机化学 物理 生物化学 化学工程 计算机科学 复合材料 内科学 催化作用 光电子学 物理化学 电极 冶金 遗传学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 6071474
求助须知:如何正确求助?哪些是违规求助? 7902985
关于积分的说明 16340155
捐赠科研通 5211752
什么是DOI,文献DOI怎么找? 2787572
邀请新用户注册赠送积分活动 1770300
关于科研通互助平台的介绍 1648148